MODIFIED RELEASE
OXYCODONE/NALOXONE1
12-hourly dosing
OXYCODONE2
12-hourly dosing
MORPHINE3,4
MS Contin® tablets
modified release
morphine sulfate
12-hourly dosing
MS Mono® capsules
modified release
morphine sulfate
24-hourly dosing
BUPRENORPHINE5,6
transdermal buprenorphine
matrix patch
7-day dosing
BUPREDERMAL® patch
transdermal buprenorphine
matrix patch
7-day dosing
IMMEDIATE RELEASE
OXYCODONE7,8
capsules & liquid
immediate release
oxycodone hydrochloride
4- to 6-hourly dosing
Capsules must not be opened, chewed or crushed
injection or infusion
oxycodone
hydrochloride
injection or infusion
MORPHINE9,10
SEVREDOL® tablets
immediate release morphine sulfate
4-hourly dosing
ORDINE®
oral solution
immediate release
morphine hydrochloride
4-hourly dosing
HYDROMORPHONE11,12
DILAUDID® tablets
immediate release hydromorphone hydrochloride
4-hourly dosing
DILAUDID®/ DILAUDID®-HP injection
hydromorphone hydrochloride
injection or infusion
Mundipharma is not promoting the use of strong opioids (excluding the 7-day buprenorphine transdermal patch) in chronic non-cancer pain.
Please review Product Information and State and Federal regulations before prescribing.
For full TARGIN® tablets prescribing information, please click here.
For full OxyContin® tablets prescribing information, please click here.
For full MS Contin® tablets prescribing information, please click here.
For full MS Mono® capsules prescribing information, please click here.
For full NORSPAN® patch prescribing information, please click here.
For full Bupredermal® patch, prescribing information, please click here.
For full OxyNorm® capsules and OxyNorm® liquid prescribing information, please click here.
For full OxyNorm® injection prescribing information, please click here.
For full SEVREDOL® tablets prescribing information, please click here.
For full ORDINE® oral solution prescribing information, please click here.
For full DILAUDID® tablets prescribing information, please click here.
For full DILAUDID®-HP Injection prescribing information, please click here.
Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is required at initiation, maintenance and tapering of opioid therapy.
WARNINGS
Limitations of use: Because of the risks associated with the use of opioids, TARGIN® Modified Release Tablets, OxyContin® modified release tablets, MS CONTIN® modified release tablets, MS MONO® modified release capsules, NORSPAN® patch, BUPREDERMAL® patch, OxyNorm® capsules and liquid, OxyNorm® solution for injection or infusion, SEVREDOL® tablets, ORDINE® oral solution, DILAUDID® oral liquid and tablets, DILAUDID®/DILAUDID®-HP INJECTION should only be used in patients for whom other treatment options, including non-opioid analgesics, are ineffective, not tolerated or otherwise inadequate to provide appropriate management of pain.
There are risks of hazardous and harmful use which can lead to overdose and death; life threatening respiratory depression. Concomitant use of benzodiazepines, gabapentinoids, antihistamines, tricyclic antidepressants, anti psychotics, cannabis or other central nervous system (CNS) depressants, including alcohol may result in profound sedation, respiratory depression, coma, and death. For full details, please see section 4.4 Special Warnings and Precautions for Use in full Product Information.
PBS Information: TARGIN® tablets, NORSPAN® patch, Bupredermal® patch, OxyContin® tablets, MS Contin® tablets and MS Mono® capsules. Authority required (STREAMLINED 10755, 10748, 10752). Chronic severe pain.
Refer to PBS schedule for full authority information, including increased maximum quantities and/or repeats.
PBS Information: MS Contin® tablets (200mg). Authority required. Chronic severe disabling pain.
Refer to PBS Schedule for full Authority Required information.
PBS Information: SEVREDOL® tablets. Restricted benefit. Severe cancer pain. Refer to PBS schedule for full restricted benefit information. Authority required for increased maximum quantities and/or repeats.
Refer to PBS Schedule for full Authority Required information.
PBS Information: OxyNorm® capsules, OxyNorm® liquid, ORDINE® oral solution 2mg/1mL, 5mg/1mL, 10mg/1mL, DILAUDID® tablets, liquid, DILAUDID® injection 2mg in 1mL and DILAUDID®-HP 10mg in 1mL injection. Restricted benefit. Severe pain. Refer to PBS schedule for full restricted benefit information. Authority required for increased maximum quantities and/or repeats.
Refer to PBS Schedule for full Authority Required information.
PBS Information: OxyNorm® capsules 5mg 10-capsules.
Restricted Benefit. Short term treatment of acute severe pain.
PBS Information: OxyNorm® injection, ORDINE® oral solution 1mg/1mL and DILAUDID®-HP 50mg in 1mL are not listed on the PBS.
Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/. Adverse events can also be reported to Mundipharma at drugsafety@mundipharma.com.au.
References:
1. TARGIN® Modified Release Tablets Product Information, June 2023.
2. OxyContin® Modified Release Tablets Product Information, July 2023.
3. MS CONTIN® TABLETS Product Information, May 2023.
4. MS MONO® MODIFIED RELEASE CAPSULES Product Information, May 2023.
5. NORSPAN® PATCH Product Information, July 2023.
6. BUPREDERMAL® PATCH Product Information, July 2023.
7. OxyNorm® Capsules and Liquid Product Information, July 2023.
8. OxyNorm® solution for injection or infusion Product Information, July 2023.
9. SEVREDOL® TABLETS Product Information, May 2023.
10. ORDINE® ORAL SOLUTION Product Information, June 2022.
11. DILAUDID® ORAL LIQUID and TABLETS Product Information, July 2023.
12. DILAUDID®/DILAUDID®-HP INJECTION Product Information, July 2023.
® TARGIN, NORSPAN, BUPREDERMAL, OXYCONTIN, OXYNORM, MS CONTIN, MS MONO, SEVREDOL and DILAUDID are registered trade marks of Mundipharma. ORDINE is a registered trade mark of Pfizer (Perth) Pty Ltd and is used under licence. Mundipharma Pty Limited ABN 87 081 322 509. Sydney, NSW 2000. Tel: 1800 188 009. FD23487 AU-TARG-2300004 September 2023.